DataMeds AI Terminates Second Amended LOI With EOS, Scilex, Datavault, REBOOT
MEDS sits 84% above its 52-week low of $0.823.
Summary
DataMeds AI terminated the Second Amended and Restated LOI with EOS, Scilex, Datavault, HBA, THI and REBOOT effective November 3, 2026, citing market conditions. No termination fees are owed and no shares will be issued under the LOI; the REBOOT GLP-1 license and Datavault PharmacyChain agreement remain in effect.
Key Events · M&A and Partnerships · MEDS
-
LOI Terminated Effective November 3
Citing market conditions, DataMeds sent written notice terminating the Second Amended and Restated LOI dated October 19, 2026 with EOS, Scilex, Datavault, HBA, THI and REBOOT, effective immediately.
-
No Fees Owed, No Shares Issued
The company states it owes no fees or obligation from the termination and will no longer issue any shares related to the 2nd LOI, removing the equity issuance that the deal contemplated.
-
Two Agreements Survive Termination
The exclusive REBOOT license for GLP-1 user management dated October 13, 2026 and the Datavault PharmacyChain agreement dated November 24, 2025 remain in full force; no shares were issued to Datavault under that agreement.
-
Reversal of October 26 Announced Deal
The terminated LOI was the transaction disclosed in the October 26, 2026 8-K that would have lifted partner ownership to roughly 89.5% and cut public holders' stake; that restructuring is now off.
Analysis · MEDS · Trade & Services
Citing market conditions, DataMeds walked away from the stock-funded IP acquisition and licensing package it announced on October 26. That deal was the centerpiece of the company's stated plan to hand roughly 89.5% ownership to partners, so its collapse removes both the asset acquisitions and the equity restructuring that went with them. No termination fees are owed, the company says, and no shares will be issued under the LOI, which removes a large potential dilution overhang. What survives is the REBOOT GLP-1 license and the Datavault PharmacyChain agreement, leaving the operating story narrower than what was pitched two weeks ago. Against a going-concern warning and Nasdaq equity deficiency disclosed in the Q2 10-Q, the company now has to find another route to capital and to the assets the LOI was meant to deliver.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $1.51 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.82 to $35.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.